← agilon health overview

agilon health vs CVS Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

agilon health Inc (AGL)

CVS Health Corp (CVS)

Q3 2026
▲3▼1

CVS Q3: Earnings Beat, Guidance Raised, But 2027 Caution and Breakup Bill Weigh

  • Q2 Earnings Beat and Raised 2026 Guidance CVS reported Q2 earnings above estimates and raised its 2026 outlook for both pharmacy and Aetna, signaling stronger profitability and boosting investor confidence.

    This is a key positive event that drove the stock during the period.

  • FTC Settlement and Aetna Turnaround The FTC settlement removed a major legal cloud, while Aetna's turnaround and $2 billion in Medicare Advantage bonuses improved profitability, lifting the stock.

    These developments reduced uncertainty and improved financial performance.

  • Health Services Growth and Walgreens Closures Health Services revenue rose 11.5%, and Walgreens store closures are driving more customers to CVS pharmacies, supporting revenue growth.

    These factors contributed to positive momentum in the period.

  • Cautious 2027 Guidance and Regulatory Threats CVS issued cautious 2027 guidance due to Caremark membership declines, 340B headwinds, and GLP-1 competition; shares fell 8%. Senator Warren's bill to break up vertical integration also threatens its structure.

    These risks capped gains and pressured the stock during the period.

September 2026
▲3▼1

CVS Raises Guidance Across All Units, But Cost and Regulatory Pressures Persist

  • CVS raises 2026 profit guidance for pharmacy and Aetna units CVS lifted full-year profit guidance for its pharmacy segment to at least $6.4 billion and its Aetna insurance unit to $5.03–$5.37 billion, both well above prior targets. This shows the company's turnaround is working, which supports the stock price.

    This is the core new positive event of the period, directly raising profit expectations and boosting investor confidence.

  • Walgreens closures hand CVS suburban pharmacy customers Walgreens is closing about 1,200 stores through 2027, pushing suburban customers to CVS without any marketing effort. CVS is also opening small-format stores and adding GLP-1 access, which should lift pharmacy sales and market share.

    This is a new competitive development that directly benefits CVS's pharmacy business and is not in earlier reports.

  • Health Services revenue jumps 11.5% with strong selling season CVS's Health Services segment posted $51.8 billion in Q2 revenue, up 11.5%, and adjusted operating income rose 10% to $1.73 billion. The 2026 selling season brought over $6 billion in new sales, well above historical averages, signaling future growth.

    This new segment-level detail shows broad-based strength beyond the headline earnings beat, supporting the bull case.

  • Elevated medical costs and regulatory pricing pressure linger CVS said at a conference it still faces elevated medical costs, which dragged managed care stocks. Separately, regulatory drug price cuts under the Inflation Reduction Act continue to pressure pharmacy revenues, though profit impact is limited so far.

    This is the main counterweight to the positive guidance news, reminding investors that cost and regulatory headwinds remain unresolved.

Latest
▲3▼1

CVS Raises Guidance Across All Units, But Cost and Regulatory Pressures Persist

  • CVS raises 2026 profit guidance for pharmacy and Aetna units CVS lifted full-year profit guidance for its pharmacy segment to at least $6.4 billion and its Aetna insurance unit to $5.03–$5.37 billion, both well above prior targets. This shows the company's turnaround is working, which supports the stock price.

    This is the core new positive event of the period, directly raising profit expectations and boosting investor confidence.

  • Walgreens closures hand CVS suburban pharmacy customers Walgreens is closing about 1,200 stores through 2027, pushing suburban customers to CVS without any marketing effort. CVS is also opening small-format stores and adding GLP-1 access, which should lift pharmacy sales and market share.

    This is a new competitive development that directly benefits CVS's pharmacy business and is not in earlier reports.

  • Health Services revenue jumps 11.5% with strong selling season CVS's Health Services segment posted $51.8 billion in Q2 revenue, up 11.5%, and adjusted operating income rose 10% to $1.73 billion. The 2026 selling season brought over $6 billion in new sales, well above historical averages, signaling future growth.

    This new segment-level detail shows broad-based strength beyond the headline earnings beat, supporting the bull case.

  • Elevated medical costs and regulatory pricing pressure linger CVS said at a conference it still faces elevated medical costs, which dragged managed care stocks. Separately, regulatory drug price cuts under the Inflation Reduction Act continue to pressure pharmacy revenues, though profit impact is limited so far.

    This is the main counterweight to the positive guidance news, reminding investors that cost and regulatory headwinds remain unresolved.

August 2026
▲2▼1

CVS's Aetna Turnaround Delivers, But Breakup Bill and 2027 Headwinds Loom

  • Aetna's lower medical costs drive earnings beat and raised guidance CVS's Aetna insurance unit benefited from lower medical costs in Q2, helping CVS beat earnings estimates and raise its 2026 adjusted EPS guidance to $7.90–$8.10. This shows the turnaround is working, which supports the stock price.

    This is the core positive driver this period, showing real profit improvement that directly lifts investor confidence.

  • Senator Warren pushes bill to break up CVS's vertical integration Senator Elizabeth Warren is pushing a bipartisan bill that would force CVS to split its insurance and pharmacy businesses. If passed, this would fundamentally change how CVS operates and could hurt profits, creating uncertainty that weighs on the stock.

    This is a new regulatory threat with potential to reshape the company, directly answering why CVS faces downward pressure.

  • CVS revamps weight management program with Eli Lilly partnership CVS expanded its weight management program, partnering with Eli Lilly to offer Zepbound through its app and lowering MinuteClinic visits to $29. This aims to capture growing demand for GLP-1 drugs, which could boost pharmacy traffic and sales.

    This is a new strategic move to capture a high-growth market, showing how CVS is positioning for future demand.

  • Strong earnings momentum but 2027 headwinds remain CVS's Q2 earnings rose 42.5% and cash flow is strong, but management warned of 340B drug pricing pressure and lower pharmacy benefit membership in 2027. The stock trades cheaply, but these unresolved risks keep a lid on gains.

    This captures the balance of positive momentum against real future challenges, giving a fair picture of what's driving the stock.

▲2▼1

CVS's Aetna Turnaround Delivers, But Breakup Bill and 2027 Headwinds Loom

  • Aetna's lower medical costs drive earnings beat and raised guidance CVS's Aetna insurance unit benefited from lower medical costs in Q2, helping CVS beat earnings estimates and raise its 2026 adjusted EPS guidance to $7.90–$8.10. This shows the turnaround is working, which supports the stock price.

    This is the core positive driver this period, showing real profit improvement that directly lifts investor confidence.

  • Senator Warren pushes bill to break up CVS's vertical integration Senator Elizabeth Warren is pushing a bipartisan bill that would force CVS to split its insurance and pharmacy businesses. If passed, this would fundamentally change how CVS operates and could hurt profits, creating uncertainty that weighs on the stock.

    This is a new regulatory threat with potential to reshape the company, directly answering why CVS faces downward pressure.

  • CVS revamps weight management program with Eli Lilly partnership CVS expanded its weight management program, partnering with Eli Lilly to offer Zepbound through its app and lowering MinuteClinic visits to $29. This aims to capture growing demand for GLP-1 drugs, which could boost pharmacy traffic and sales.

    This is a new strategic move to capture a high-growth market, showing how CVS is positioning for future demand.

  • Strong earnings momentum but 2027 headwinds remain CVS's Q2 earnings rose 42.5% and cash flow is strong, but management warned of 340B drug pricing pressure and lower pharmacy benefit membership in 2027. The stock trades cheaply, but these unresolved risks keep a lid on gains.

    This captures the balance of positive momentum against real future challenges, giving a fair picture of what's driving the stock.

July 2026
▲3▼1

CVS beats Q2, raises guidance, but cautious 2027 outlook sinks shares

  • Aetna turnaround and Medicare Advantage bonuses CVS quantified $3–$4 of embedded earnings per share from its Aetna turnaround and expects $2 billion in 2026 Medicare Advantage quality bonuses, signaling improved profitability in its insurance unit.

    This shows a key profit driver that boosted investor confidence during the period.

  • FTC settlement removes legal uncertainty CVS reached a settlement with the FTC, removing a major legal cloud that had been hanging over the company and allowing management to focus on operations.

    This was a new positive development that reduced regulatory risk for CVS.

  • Q2 earnings beat and raised guidance CVS reported Q2 adjusted EPS of $2.58 and revenue over $106 billion, beating estimates, and raised its 2026 guidance while setting a preliminary 2027 EPS floor of $8.44, about 13% growth.

    This is the core financial update that drove the stock's initial positive reaction.

  • Cautious 2027 outlook and persistent headwinds Despite the Q2 beat, CVS gave cautious 2027 guidance, citing expected Caremark membership declines, continued 340B headwinds, and intense GLP-1 competition from Walmart and Amazon. Shares fell 8% on the outlook.

    This explains the main negative force that pulled the stock down during the period.

▲3▼1

CVS beats and raises guidance, but cautious 2027 outlook and GLP-1 competition weigh

  • Q2 beat and raised 2026 guidance CVS reported Q2 adjusted EPS of $2.58 on revenue over $106 billion, beating estimates, and raised 2026 adjusted EPS guidance to $7.90–$8.10. Adjusted operating income jumped 35% to about $5.2 billion, showing the Aetna turnaround is delivering real profit growth.

    This is the core new financial result that directly moves the stock and confirms the recovery story.

  • 2027 EPS floor and 13% growth target Management set a preliminary 2027 adjusted EPS floor of $8.44, about 13% growth from 2026, and forecast at least $11.5 billion in operating cash flow. This gives investors a concrete multi-year earnings path, supporting the stock despite near-term caution.

    It provides forward visibility that investors use to value the stock and judge the durability of the turnaround.

  • GLP-1 push with $29 MinuteClinic visits and Lilly deal CVS revamped its weight management program with $29 virtual visits and a Lilly collaboration for transparent Zepbound pricing, aiming to capture GLP-1 prescriptions as employers drop coverage. This could boost pharmacy traffic and customer loyalty, though competition from Walmart and Amazon is intense.

    It is a new growth initiative that could drive demand and offset other pressures, directly affecting future revenue.

  • Cautious guidance and 2027 headwinds Despite the beat, CVS gave cautious guidance, sending shares down 8% on the day. Management flagged expected membership declines in Caremark and continued 340B headwinds for 2027, which could pressure future profits and temper the upbeat long-term targets.

    It is the main counterweight that explains why the stock fell even after strong results and raised guidance.

▲3▼1

CVS Gains on Aetna Turnaround, Medicare Bonus, and FTC Settlement

  • Aetna turnaround quantified Management quantified $3–$4 of embedded EPS from Aetna's margin recovery, raised 2025 guidance, and trimmed unprofitable Medicare Advantage and ACA plans. This gives investors a concrete path to higher profits, pushing the stock up.

    It explains the core profit-recovery story driving the stock's 57% surge.

  • Medicare Advantage bonus payments CVS is expected to receive $2 billion in federal quality bonus payments for 2026, as more plans earn four stars or higher. This is direct extra revenue for its insurance unit, supporting earnings and the stock price.

    It is a new, material cash inflow that boosts CVS's Medicare Advantage profitability.

  • FTC settlement removes legal overhang CVS Caremark settled the FTC's rebate lawsuit, agreeing to pricing reforms like capping insulin at $25 and increasing transparency. This removes a major legal uncertainty, which investors see as reducing risk and lifting the stock.

    It resolves a key regulatory threat that had been weighing on the shares.

  • Legal and regulatory headwinds persist CVS agreed to pay $440 million to settle a false billing case, and Henry Ford Health sued over $29 million in 340B drug discounts. These add costs and uncertainty, but are smaller than the positive drivers and may not derail the recovery.

    It provides a fair counterweight, showing that legal risks remain even as the core business improves.

Q2 2026
▲2▼2

CVS expands GLP-1 access but faces antitrust and Medicare scrutiny

  • GLP-1 access program CVS launched a GLP-1 support program across 9,000 pharmacies, offering $49 virtual visits and medications as low as $25/month. This could boost retail pharmacy revenue and patient demand, pushing the stock up.

    This is a new initiative that directly drives future revenue and demand for CVS's pharmacy and clinic services.

  • Florida antitrust probe Florida's Attorney General opened an antitrust investigation into CVS's pharmacy and PBM operations, demanding documents by July 28. This regulatory risk could lead to fines or business changes, weighing on the stock.

    This is a new regulatory threat that could result in penalties or operational restrictions, directly impacting CVS's valuation.

  • Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care by CVS and other Medicare Advantage insurers. This scrutiny could lead to stricter regulations or reputational damage, pressuring the stock.

    This new negative media coverage raises regulatory and reputational risks that could affect CVS's Medicare Advantage business.

  • Strong Q1 earnings beat CVS reported Q1 revenue of $100.4 billion, beating estimates by 6.3% and up 6.2% year-over-year. This strong financial performance supports the stock price and investor confidence.

    This is a new earnings result that demonstrates CVS's financial health and outperformance versus peers.

June 2026
▲2▼2

CVS expands GLP-1 access but faces antitrust and Medicare scrutiny

  • GLP-1 access program CVS launched a GLP-1 support program across 9,000 pharmacies, offering $49 virtual visits and medications as low as $25/month. This could boost retail pharmacy revenue and patient demand, pushing the stock up.

    This is a new initiative that directly drives future revenue and demand for CVS's pharmacy and clinic services.

  • Florida antitrust probe Florida's Attorney General opened an antitrust investigation into CVS's pharmacy and PBM operations, demanding documents by July 28. This regulatory risk could lead to fines or business changes, weighing on the stock.

    This is a new regulatory threat that could result in penalties or operational restrictions, directly impacting CVS's valuation.

  • Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care by CVS and other Medicare Advantage insurers. This scrutiny could lead to stricter regulations or reputational damage, pressuring the stock.

    This new negative media coverage raises regulatory and reputational risks that could affect CVS's Medicare Advantage business.

  • Strong Q1 earnings beat CVS reported Q1 revenue of $100.4 billion, beating estimates by 6.3% and up 6.2% year-over-year. This strong financial performance supports the stock price and investor confidence.

    This is a new earnings result that demonstrates CVS's financial health and outperformance versus peers.

▲2▼2

CVS expands GLP-1 access but faces antitrust and Medicare scrutiny

  • GLP-1 access program CVS launched a GLP-1 support program across 9,000 pharmacies, offering $49 virtual visits and medications as low as $25/month. This could boost retail pharmacy revenue and patient demand, pushing the stock up.

    This is a new initiative that directly drives future revenue and demand for CVS's pharmacy and clinic services.

  • Florida antitrust probe Florida's Attorney General opened an antitrust investigation into CVS's pharmacy and PBM operations, demanding documents by July 28. This regulatory risk could lead to fines or business changes, weighing on the stock.

    This is a new regulatory threat that could result in penalties or operational restrictions, directly impacting CVS's valuation.

  • Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care by CVS and other Medicare Advantage insurers. This scrutiny could lead to stricter regulations or reputational damage, pressuring the stock.

    This new negative media coverage raises regulatory and reputational risks that could affect CVS's Medicare Advantage business.

  • Strong Q1 earnings beat CVS reported Q1 revenue of $100.4 billion, beating estimates by 6.3% and up 6.2% year-over-year. This strong financial performance supports the stock price and investor confidence.

    This is a new earnings result that demonstrates CVS's financial health and outperformance versus peers.

© 2026 MarketDXWhy